Kuros Biosciences Unveils MagnetOs MIS System Amid Global Growth
Kuros Biosciences Unveils MagnetOs MIS Delivery System
Kuros Biosciences, a pioneering force in biologic technologies, has successfully completed the first cases using its groundbreaking MagnetOs MIS Delivery System. This innovative sterile and prefilled single-use system is designed specifically for Minimally Invasive Surgery (MIS) in spinal procedures. This launch comes after receiving FDA 510(k) clearance, underscoring the company's commitment to improving surgical techniques and outcomes.
First Successful Cases and Expert Feedback
The initial cases were performed by Dr. Daniel Park, a well-respected orthopedic spine surgeon. Dr. Park stated, "MagnetOs MIS delivered smooth and precise graft placement in what is often a challenging scenario for minimally invasive transforaminal lumbar interbody fusion (TLIF). The system's design facilitates immediate delivery without the need for preparation or thawing, enhancing efficiency in the operating room." Kuros is enthusiastic about rolling out the full commercial launch of this system in the near future.
Innovative Technology Behind MagnetOs
MagnetOs MIS represents a leap forward in bone grafting technology. It leverages the proprietary NeedleGrip™ submicron surface technology, aiming to engage the body’s immune system to stimulate natural bone growth. This advanced system enables surgeons to achieve graft placement up to three times faster compared to traditional funnel-based methods, which is a crucial advantage in high-pressure surgical environments.
Impressive Clinical Outcomes
The efficacy of MagnetOs is supported by compelling clinical evidence. A recent retrospective study reported a 94.4% fusion rate across 36 treated levels in patients who underwent both minimally invasive and open TLIF procedures. Remarkably, many participants had significant comorbidities, highlighting the versatility and reliability of MagnetOs for diverse patient populations. Previous Level I randomized clinical studies have shown MagnetOs is nearly twice as effective as autograft in achieving successful fusions in posterolateral fusion surgeries.
Expanding Global Presence
In addition to the U.S. launch, Kuros Biosciences is also making strides in international markets. The recent approval of MagnetOs Granules by ANVISA in Brazil, along with the approval of MagnetOs Putty, signifies Kuros's commitment to expanding its footprint in South America. These developments reflect a growing global demand for MagnetOs as a dependable option for bone grafting, which has been welcomed by the medical community.
Leadership Insights
Chris Fair, CEO of Kuros Biosciences, remarked on these milestones: "We are proud to deliver what surgeons seek: a system that combines precision, speed, and reliable outcomes. Minimally invasive surgical techniques are gaining traction, and our MagnetOs products are positioned to support this trend effectively. The approval of our products in Brazil opens further avenues for growth in key international markets. We maintain optimism about the robust market potential for our innovative technology."
Contact Information
For further inquiries, please contact:
Alexandre Müller, Investor Relations
Tel: +41 43 268 32 31
Email: IR@kurosbio.com
Daniel Geiger, Chief Financial Officer
Tel: +41 44 733 47 41
Email: daniel.geiger@kurosbio.com
Frequently Asked Questions
What is the MagnetOs MIS Delivery System?
The MagnetOs MIS Delivery System is a sterile, prefilled, and single-use delivery system designed for minimally invasive spinal surgeries, significantly improving graft placement efficiency.
Who performed the first case using MagnetOs MIS?
Dr. Daniel Park, an orthopedic spine surgeon, successfully performed the initial case using the new MagnetOs MIS Delivery System.
What technology does MagnetOs utilize?
MagnetOs employs NeedleGrip™ submicron surface technology, which stimulates the immune system to promote natural bone growth, enhancing surgical outcomes.
How effective is MagnetOs in clinical studies?
Clinical data reveals a 94.4% fusion rate in various spine surgeries utilizing MagnetOs, showcasing its effectiveness compared to traditional graft options.
What is Kuros Biosciences’ strategy for international markets?
Kuros is expanding its global presence, recently gaining approvals in Brazil, thereby increasing access to its innovative bone grafting solutions in key markets worldwide.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.